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Summary
Background An estimated 150 million people worldwide are infected with hepatitis C virus (HCV). HIV co-infection 
accelerates the progression of HCV and represents a major public health challenge. We aimed to determine the 
epidemiology of HCV and the prevalence of HIV co-infection in sub-Saharan Africa.
Methods We searched Medline and Embase (Ovid) from Jan 1, 2002, to Dec 31, 2014, for studies containing data for 
HCV seroprevalence in diﬀ erent population groups in WHO-deﬁ ned regions of sub-Saharan Africa. We estimated 
pooled regional prevalence estimates with a DerSimonian-Laird random-eﬀ ects model. Data were further stratiﬁ ed by 
risk factor and HIV status.
Findings We included 213 studies from 33 countries in sub-Saharan Africa, comprising 287 separate cohorts with 
1 198 167 individuals. The pooled HCV seroprevalence from all cohorts was 2·98% (95% CI 2·86–3·10). The pooled HCV 
seroprevalence was 2·65% (95% CI 2·53–2·78) across all 185 low-risk cohorts, 3·04% (2·23–3·84) in antenatal clinic 
groups, 1·99% (1·86–2·12) in blood donors, but 6·9% (6·1–7·5) in other general population cohorts. The pooled 
seroprevalence of HCV was 11·87% (95% CI 7·05–16·70) across all high-risk groups and 9·95% (6·79–13·11) in patients 
with liver disease. 101 cohorts included HIV-positive samples tested for HCV (42 648 individuals), with a pooled 
seroprevalence of 5·73% (95% CI 4·90–6·56).
Interpretation We recorded a high seroprevalence of HCV across populations of sub-Saharan Africa, including in 
HIV-positive adults, with evidence of regional variation in the general population. Monitoring of antenatal HCV 
prevalence might be a helpful indicator of population trends in HCV infection; however, larger population surveys are 
needed to monitor these trends. Access to prevention and treatment needs to be improved for both monoinfected and 
co-infected individuals.
Funding None.
Introduction
An estimated 130 million to 150 million individuals 
worldwide are infected with hepatitis C virus (HCV)1,2 and 
the infection contributes substantially to the global 
burden of disease.3,4 No vaccine is yet on the market for 
HCV; therefore, control of the epidemic relies on 
preventive measures (eg, screening of blood products, 
opiate substitution, and needle exchange) and on 
treatment to prevent progression to cirrhosis and 
hepatocellular carcinoma. Until recently, the complexity 
of HCV treat ment was a barrier to wider use; standard 
treatment involved injectable pegylated interferon and 
ribavirin tablets in a long and complex regimen dependent 
on viral genotype and requiring frequent monitoring.5,6 
HCV management has been revolutionised by recently 
licensed directly acting antiviral drugs, including protease 
inhibitors, NS5B inhibitors (eg, sofosbuvir7,8), and NS5A 
inhibitors (eg, ledipasvir and daclatasvir), which allow for 
shortened treatment durations with improved success 
rates without the use of interferon.9,10 These new 
treatments could substantially reduce the clinical and 
operational barriers to treatment throughout the world, 
provided they are accessible and aﬀ ordable.6,11
Accurate epidemiological information is essential to 
inform treatment and control priorities at national and 
regional levels. In particular, data are needed on the burden 
of co-infection with HIV in view of the poor outcomes for 
HCV in this population.12 Such data are scarce for many 
regions, particularly parts of sub-Saharan Africa, partly 
because the public health importance of HCV infection has 
only recently been recognised.3 A 2002 review13 of HCV 
epidemiology in sub-Saharan Africa estimated the overall 
prevalence of HCV to be 3%, with substantial regional 
variation. A further review14 of the association between HIV 
and hepatitis B and C showed a relative risk of HIV co-
infection of 1·60 (95% CI 1·05–2·45). However, both 
analyses identiﬁ ed few data for the prevalence of HIV–HCV 
co-infection, which is crucial to the policy debate 
surrounding expansion of HCV treatment.
We did this systematic review and meta-analysis to 
determine the seroprevalence of HCV and the prevalence 
of HCV–HIV co-infection across sub-Saharan Africa.
Methods
Search strategy and selection criteria
We searched Medline and Embase (Ovid) from Jan 1, 2002, 
to Dec 31, 2014, for all reports that possibly contained data 
for HCV seroprevalence in diﬀ erent population groups. 
The appendix provides full details of the search strategy 
and includes terms to assess the availability of data on 
See Online for appendix
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HIV–HCV co-infection. Included reports were published 
between Jan 1, 2002, and Dec 31, 2014.13 One author (NJ) 
extracted data and another author (VBR) veriﬁ ed these data 
in full on the basis of country, year of publication, year of 
collection, study type, study design, HCV assay used, study 
population, sample size, proportion of men, age, HCV 
seroprevalence, PCR prevalence, genotype (including 
proportion of each genotype when available), subtypes, 
and prevalence of HIV co-infection.
Countries included in the study were limited to those 
in sub-Saharan Africa, grouped according to WHO Africa 
regions. To directly compare results with previous 
published analyses, we excluded six countries: Algeria, 
Cape Verde, Comoros, Mauritius, São Tomé and Príncipe, 
and Seychelles. We included three countries not listed in 
the WHO regional list: Sudan, and South Sudan after 
2012], Djibouti, and Somalia. We included studies 
published in English and French. Studies were not 
rejected on the basis of sample size or design (including 
both retrospective and prospective studies), and included 
cross-sectional national surveys and surveys from screen-
ing programmes, antenatal clinics, blood donations, 
hospitals, and other institutions such as prisons. We 
excluded studies that did not state sample size or HCV 
seroprevalence or identify the HCV diagnostic assays 
used. No study was discounted on the basis of HCV 
diagnostic assay; this review includes studies using both 
non-conﬁ rmatory (ELISA, EIA, screening assays) and 
conﬁ rmatory (RIBA, western blots, PCR) assays. The 
prevalence of detectable HCV RNA was included when 
available.
Cohort classiﬁ cation
We separated cohorts either by time of collection (if this 
was deﬁ ned in the study) or by collection site—ie, 
antenatal clinic or blood donor. We also separated control 
cohorts from intervention cohorts in case-control studies. 
If a study included a separate HIV subanalysis, we 
included this cohort as separate within the HIV pooled 
prevalence, but did not count it overall as a separate 
cohort. We initially categorised cohort studies as either 
low risk or high risk with deﬁ nitions similar to those used 
previously.13 The low-risk category followed the deﬁ nition 
from Madhava and colleagues13—namely, according to the 
setting from which the samples were obtained and tested. 
The aggregated low-risk group included pregnant women 
at antenatal clinics, blood donors, and other samples that 
were obtained from the general population—ie, randomly 
selected communities whether rural or urban, students, 
and samples from inpatients or outpatients seeking care 
for non-hepatic illnesses or who had not had multiple 
blood transfusions. We divided the high-risk group into 
two groups: patients with known liver disease, whether 
acute or chronic; and patients who had no documented 
liver disease but who had high-risk exposures such as 
multiple blood transfusions, haemodialysis, renal 
transplants, sickle-cell disease, or injecting drug use. We 
grouped HIV-infected cohorts separately to assess the 
prevalence of HIV and HCV co-infection.
Statistical analysis
We calculated point estimates and 95% CIs for the 
proportion of people with HCV in each study. We 
estimated prevalence of HCV by WHO region by pooling 
of data from each study. Data were pooled with a 
DerSimonian-Laird random-eﬀ ects model,15 which 
incorporates an estimate of between-study variance, 
allowing that the true eﬀ ect size could vary between 
studies.16 To assess between-study heterogeneity for the 
estimates of pooled prevalence by region, the  t² statistic 
was calculated. The variance of raw proportions was 
stabilised with a Freeman-Tukey type arcsine square-root 
transformation.17 Several methods of pooling of 
proportions exist; the Freeman-Tukey method works well 
with both ﬁ xed-eﬀ ects and random-eﬀ ects meta-
analysis.18,19 We further stratiﬁ ed data by risk group and 
HIV status. We did analyses with Stata (version 12).
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Figure 1: Study selection
HCV=hepatitis C virus.
964 records identified
 371 via Medline
 593 via Embase
697 screened by title and abstract
305 full-text articles assessed for eligibility
392 excluded
 234 irrelevant reports
 73 review articles
 73 conference abstracts
 12 genotype studies
267 duplicates removed
97 excluded
 27 had no prevalence data
 8 HCV assay not specified
 16 identical or overlapping 
  cohorts
 11 due to language
 31 not accessible
 1 no sample size
 3 methods not clearly stated
213 studies included in analysis
5 additional records identified 
    through bibliographic search
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Results
We included 213 studies from 33 countries in sub-Saharan 
Africa (ﬁ gure 1, appendix). These studies included data for 
287 cohorts comprising 1 198 167 individuals; 241 cohorts 
had sample sizes greater than 100 people (appendix). 
177 studies were cross-sectional surveys, 15 studies were 
retrospective cohort studies, and 19 studies were case-
control studies. Of the 287 cohorts, 81 (28%) used 
conﬁ rmatory assays to screen for the presence of anti-HCV 
antibodies and HCV RNA, 55 (19%) described testing for 
HCV RNA (ie, reported HCV prevalence based on PCR 
testing), and 39 (14%)presented data for HCV genotyping.
The estimated pooled HCV seroprevalence across all 
287 cohorts identiﬁ ed was 2·98% (95% CI 2·86–3·10; 
t² 0·06), varying widely from 6·76% (95% CI 5·98–7·55; t² 
0·05; 70 cohorts) in the central Africa region to 4·34% 
(3·99–4·70; t² 0·05; 142 cohorts) in west Africa and 0·91% 
(0·80–1·02; t² 0·02; 75 cohorts) in southeast Africa. 
142 cohorts (49%) were from the west Africa region, but 
most individuals were from southeast Africa, skewed 
by one survey from the South African Blood Service 
(732 250 samples).20 185 cohorts comprising 
1 151 337 individuals were identiﬁ ed as low-risk populations 
(appendix) representing 30 of the 33 countries. The pooled 
HCV seroprevalence in all low-risk groups aggregated, 
across all regions of sub-Saharan Africa, was 2·65% 
(ﬁ gure 2). This seroprevalence was higher than that in all 
blood donor cohorts, but lower than that in other general 
population cohorts (ﬁ gure 2).
We noted substantial regional variation among the low-
risk cohorts (ﬁ gure 1), with pooled HCV seroprevalence 
highest in the central Africa region and lowest in southeast 
Africa (ﬁ gure 2). West Africa contributed the largest 
number of cohorts (n=100) and has a seroprevalence that 
most closely approaches the overall estimate (ﬁ gure 2). The 
pooled prevalence was slightly higher in aggregated low-
risk populations than in blood donors, but this diﬀ erence 
was greatest in the central Africa region (ﬁ gure 2). The 
highest HCV seroprevalence estimate in a blood donor 
cohort included in this analysis was 14·58% from a study 
that sampled blood donated at teaching hospitals and 
privately owned blood banks in Nigeria (n=624).21
Among antenatal clinic populations, overall pooled 
HCV seroprevalence was 3·04%, similar to the aggregated 
pooled estimate for low-risk cohorts (ﬁ gure 2). However, 
ﬁ ndings from regional subanalysis, despite low cohort 
numbers, showed that the pooled HCV seroprevalence for 
antenatal clinical cohorts in central Africa was again 
substantially lower than the overall central region estimate 
in low-risk populations (ﬁ gure 2). Pooled seroprevalence 
for antenatal clinic cohorts in the west Africa region was 
higher than that in the southeast region (ﬁ gure 2).
A subanalysis of the other 88 cohorts included in the 
low-risk category—namely, samples from the general 
population in addition to inpatients and outpatients not 
deemed to be at a high risk of HCV—showed an overall 
pooled seroprevalence that was higher than the estimates 
for antenatal clinic and blood donor populations 
(ﬁ gure 2). Regional variation was substantial, with a 
pooled seroprevalence estimate in central Africa of 
12·11% compared with 2·44% in southeast Africa and 
5·74% in west Africa (ﬁ gure 2). In all regions, pooled 
estimates in these so-called other low-risk cohorts were 
higher than those in in antenatal clinic and blood donor 
populations (ﬁ gure 2).
41 cohorts across 15 countries were categorised as high 
risk for HCV infection (ﬁ gure 3, appendix). Pooled HCV 
seroprevalence estimates across all 21 high-risk exposure 
Figure 2: Estimated pooled seroprevalence of hepatitis C virus in low-risk 
populations
*Other cohorts included the general population, inpatients, and outpatients.
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Figure 3: Forest plot of estimated pooled seroprevalence of hepatitis C virus 
in high-risk populations
High-risk populations included individuals who had undergone multiple 
transfusions, injecting drug users, those who had undergone haemodialysis, 
health-care workers, and prisoners.
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cohorts were higher than those for low-risk cohorts, with 
similar values across all regions (ﬁ gures 2, 3). The estimate 
for high-risk cohorts in the central Africa region was lower 
than that for the so-called other low-risk cohorts in the 
same region, although cohort numbers are low (ﬁ gures 2, 
3). The highest HCV seroprevalence estimate identiﬁ ed 
was recorded in Kenya in a sample population of 145 
injecting drug users (46% with HCV).22 By contrast, 
analysis of the 20 liver disease cohorts showed an overall 
pooled HCV seroprevalence estimate of 9·95% (ﬁ gure 3, 
appendix). Although estimated levels of infection were 
similar in west and southeast Africa, in the central region 
the pooled seroprevalence of HCV in liver disease cohorts 
was 2·5% (ﬁ gure 3). This estimate was lower than 
estimates in this region for the aggregated low-risk cohorts 
and accorded with estimates for blood donor and antenatal 
clinic populations in the central region (ﬁ gures 2, 3).
Seroprevalence of HCV–HIV co-infection was reported 
in 101 cohorts from 27 countries; some cohorts were 
recruited as HIV-positive cohorts (n=61) and others were 
identiﬁ ed as a subgroup within the primary analysis of 
each study. 42 648 HIV-positive individuals were included 
(appendix). 75 cohorts (74%) included more than 
50 individuals. The overall pooled seroprevalence of 
HCV co-infection in HIV-infected individuals was 5·73% 
(ﬁ gure 4). Most co-prevalence studies were from 
countries in west Africa, with a pooled HCV sero-
prevalence of 6·67%, and southeast Africa, with a pooled 
HCV seroprevalence of 4·56% (ﬁ gure 4). Estimates of co-
infection in HIV-positive cohorts in all regions lie 
between those for blood donor and antenatal clinic 
cohorts and high-risk cohorts (ﬁ gure 4).
Some countries (eg, Senegal, Rwanda, Djibouti, and 
The Gambia) report fairly low HIV prevalence and low 
levels of co-infection (ﬁ gure 5). Some regions of high 
HIV prevalence (eg, Malawi, Zimbabwe, and Zambia in 
southern Africa) are estimated to have low levels of HCV 
co-prevalence (ﬁ gure 5). We noted the highest levels of 
co-prevalence in east and southeast Africa (Tanzania, 
Mozambique, and Kenya) and central Africa (Cameroon, 
Burundi, and Angola) of which only Mozambique reports 
HIV prevalence greater than 10% (ﬁ gure 5). When we 
considered only countries with either a sample size 
greater than 500 HIV-positive patients or with more than 
four HIV-positive cohorts, co-infection with HCV was 
estimated to be greater than pooled seroprevalence of 
10% in Burundi, Cameroon, Kenya, Mozambique, 
Tanzania, and Burkina Faso, and less than 5% in Uganda, 
Malawi, South Africa, and Côte d’Ivoire.
We included 40 cohorts with 3422 HCV-infected 
individuals, with a pooled HIV prevalence of 15·86% 
(95% CI 12·47–19·24). Regional breakdown showed that 
the highest rates of HIV co-infection in individuals with 
known HCV were in southeast Africa (33·42%, 95% CI 
17·50–49·35; 14 cohorts) by contrast with west Africa 
(10·05%, 6·13–13·98; 18 cohorts) and central Africa 
(5·89%, 2·49–9·31; eight cohorts). In only 52 (28%) of 
185 low-risk cohorts conﬁ rmatory assays were used to 
screen for the presence of anti-HCV antibodies. The 
estimates for pooled HCV seroprevalence overall and in 
each of the regions did not diﬀ er greatly from those in all 
general population cohorts when restricted to studies 
using conﬁ rmatory assays.
Figure 5: Estimated HCV seroprevalence in HIV-positive cohorts in relation to HIV prevalence in 15–49 year olds
HIV data are from WHO/UNAIDS, 2013.23 HCV=hepatitis C virus.
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Figure 4: Seroprevalence of HCV in HIV-positive cohorts and of HIV in HCV-
positive cohorts, by region
HCV=hepatitis C virus.
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Analysis of the 35 low-risk cohorts that also reported 
PCR testing showed that the pooled proportion of 
positive serology samples that were PCR positive was 
51·27% (ﬁ gure 6). Data for the genotype distribution of 
HCV were reported for only 39 cohorts in 19 countries.
Discussion 
We recorded a high seroprevalence of HCV across 
populations of sub-Saharan Africa, including in HIV-
positive adults, when all samples were analysed 
collectively, with similar, slightly lower, levels of infection 
when analysis was limited to low-risk samples, in 
accordance with previous deﬁ nitions. We identiﬁ ed 
regional variation among groups considered low risk, 
with the highest pooled seroprevalence within the central 
Africa region. In all regions, estimates of HCV 
seroprevalence were lower in blood donor cohorts and 
antenatal clinic groups than within aggregated low-risk 
cohorts. However, the regional and overall pooled 
seroprevalences in the so-called other low-risk groups 
were higher. These cohorts included individuals in 
health-care settings as part of case-control studies or 
convenience sampling. Such settings are associated with 
transmission of HCV due to potential nosocomial 
transmission through fomites or non-exposure prone 
procedures including venepuncture and cannulation,14,24–26 
and might explain why recorded prevalence was higher 
than in population surveys.
The overall estimates for HCV seroprevalence are very 
similar to those described previously, despite the 
estimates being based on diﬀ erent studies and diﬀ erent 
time periods.13 This similarity gives more certainty to the 
robustness of these estimates and suggests no major 
change in HCV prevalence between the periods of study. 
However, larger population surveys, repeated over time, 
are needed to monitor these trends. Because population 
surveys are time consuming and expensive, other com-
plementary methods are needed to monitor changes in 
prevalence. The ﬁ nding that HCV prevalence in 
antenatal cohorts is similar to that in the overall 
population suggests that antenatal groups might 
represent a useful population for monitoring, 
particularly because there are many existing programmes 
testing for HIV in this group.
Previous analyses done as the HIV epidemic arose in 
sub-Saharan Africa showed little evidence of association 
between the prevalence of HIV and HCV infections.13 An 
increased relative risk of hepatitis B virus and HCV 
infection has been reported in HIV-positive populations 
compared with HIV-negative populations.14 We noted that 
the overall seroprevalence of HCV infection in HIV-
infected individuals was substantially higher than that in 
blood donor or antenatal clinic groups, and similar to that 
in general population cohorts, a ﬁ nding that was consistent 
across all regions. The highest estimates of HCV–HIV co-
infection were in countries (Tanzania, Burkina Faso, 
Cameroon, and Kenya) with a moderate prevalence of 
adult HIV (<6%, except Mozambique). By contrast, 
countries with the highest HIV prevalence (South Africa, 
Botswana, Zimbabwe, Zambia, Mozambique, and Malawi) 
were all estimated to have low to moderate levels of HCV 
co-infection (<5%, except Mozambique). Conversely, 
seroprevalence of HIV co-infection was increased in 
cohorts identiﬁ ed as HCV seropositive, except in the 
central Africa region, although our analysis included fewer 
cohorts and samples from the central Africa region than 
from southeast or west Africa. These diﬀ erences suggest 
that risk behaviours responsible for HCV transmission 
might be quite dissociated from those associated with HIV 
transmission in some regions, such as central Africa. 
Furthermore, regional diﬀ erences might be partly 
explained by risk behaviours that are speciﬁ c to one area 
(eg, scariﬁ cation or speciﬁ c medical practices), but we did 
not identify large studies that were able to explore this 
hypothesis further.
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Figure 6: Proportion of positive serology samples that were PCR positive in 35 low-risk cohorts 
See appendix for full details of the included studies.
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Although our meta-analysis of HIV–HCV co-infection 
is the largest so far, it is limited by the geographical 
distribution of the reports identiﬁ ed through the 
systematic review. Although most the reported studies 
were from the west Africa region, most samples were 
from southeast Africa, especially South Africa (including 
one large population survey). Nonetheless, the data here 
support the need for provision of HCV testing and care 
in all HIV programmes and developing programmes for 
HCV infection. Despite retrieval of a large number of 
studies, we limited our review to published articles 
retrieved from searching two databases and published in 
two languages; an expanded search including grey 
literature and additional languages (notably Arabic and 
Portuguese) might have contributed additional studies.
The quality of studies included was variable because 
most were not cross-sectional population-based surveys, 
but instead targeted speciﬁ c groups in restricted geo-
graphical regions. All the studies assessed HCV infection 
with serology, a proportion then undertook con ﬁ rmatory 
testing. The results of the PCR testing suggest the 
proportion of seropositive patients who have active disease, 
and hence need treatment, is just over 50%. The extent to 
which this ﬁ nding is a result of false-positive serology, a 
well recognised challenge, is hard to quantify. However, a 
subanalysis restricted to those general popu lation samples 
with conﬁ rmed serology showed a prevalence similar to 
that in all general population samples, suggesting that this 
issue was not major. Importantly, a large proportion of 
seropositive individuals will not need treatment and these 
data reinforce the need for larger community surveys with 
high-quality diagnostic methods, including HIV and HCV 
nucleic acid testing, for more robust prevalence estimates 
to inform develop ment of prevention and treatment 
programmes. Irrespective of the limitations of the available 
data, there is a clear unmet need for prevention and 
treatment, access to which needs to be improved for both 
mono infected and co-infected individuals.
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